FDA Grants Platform Tech Designation To Viral Vector In Sarepta's SRP-9003 For LGMD Type 2E/R4
Refinitiv1분 미만 읽기
Sarepta Therapeutics Inc 
SRPT:
U.S. FDA GRANTS PLATFORM TECHNOLOGY DESIGNATION TO THE VIRAL VECTOR USED IN SRP-9003, SAREPTA’S INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2E/R4
이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오